// App-Quantinova.ai

1251 : Allo-HSCT from MUD/MRD As a Curative Treatment in Paroxysmal Nocturnal Hemoglobinuria

Researchers

Presenter

  • Miroslaw Markiewicz

Principal Investigators

  • Anna Koclega

  • Monika Dzierzak-Mietla

  • Patrycja Zielinska

  • Ewa Mendek-Czajkowska

  • Krzysztof Bialas

  • Slawomira Kyrcz-Krzemien

Medical Centers

  • Hematology and Bone Marrow Transplantation , Medical University of Silesia, Katowice, Poland,

  • Hematology and Bone Marrow Transplantation , Medical University of Silesia, Katowice, Poland,

  • Hematology, Institute of Hematology and Transfusiology, Warsaw, Poland

Locations

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Budd-Chiari syndrome

  • Hepatitis B

  • Renal insufficiency

  • Nephrotoxicity

  • Venous thrombosis

  • Mucositis

  • Graft-versus-host disease

Biomarkers

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 34

  • Lactate dehydrogenase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Red Blood Cells

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Phosphatidylinositol

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Cyclosporine A

  • Mycophenolic acid

  • Cyclosporine eent

  • Methotrexate

  • fludarabine tablet

  • Eculizumab

  • Ovastat

  • Tacrolimus

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved